Research
Energy balance
Tirzepatide showed no meaningful benefit over semaglutide in reducing the risk of hospitalization for heart failure or all-cause mortality.
Clinicians may consider semaglutide as the preferred option over tirzepatide for this patient population.
StrongRefutesmedium confidence
Tirzepatide had no meaningfully lowered risk compared with semaglutide (HR, 0.86 [95% CI, 0.70-1.06]).
Why this rating
Based on the use of cohort studies with a large sample size.
Source
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
Nils Krüger et al. · JAMA · 2025
DOI 10.1001/jama.2025.14092
cohort · n=58333Cited 33×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In patients with cardiometabolic HFpEF, semaglutide showed a 42% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin.Strong
- In patients with cardiometabolic HFpEF, tirzepatide showed a 58% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →